Overview

Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AFQ056 in Children With Fragile X Syndrome (FXS)

Status:
Completed

Trial end date:
2013-10-01

Target enrollment:

Participant gender:

Summary

The aim of this study is to characterize the pharmacokinetics and safety/tolerability of AFQ056 in children with Fragile X Syndrome(FXS)

Phase:

Phase 1

Details

Lead Sponsor:

Novartis Pharmaceuticals